POPatrycja Okoń

Patrycja Okoń

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patrycja Okoń has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk Factors, Injury Mechanisms, and Prevention Programs for Anterior Cruciate Ligament (ACL) Injuries in Professional Football Players- A Narrative Review

    by Julianna Cholewa, Bartosz Wójtowicz, Patrycja Okoń, Jagoda Niczyporuk, Maria Suchcicka

    Background: Anterior cruciate ligament (ACL) injuries in professional football cause prolonged absence (6–12 months) and high financial burdens. Incidence remains high despite surgical advancements. Objective: To synthesize evidence on intrinsic/extrinsic risk factors, kinematic mechanisms, and prophylactic/return-to-play efficacy. Methods: A narrative review across PubMed, Scopus, Web of Science, and Google Scholar included peer-reviewed cohort studies, video analyses, and RCTs focusing on elite players. Results: Key intrinsic factors include sex disparities, fast-twitch hamstring typology, dynamic knee valgus, and neurocognitive errors (55% of pressing injuries involve poor inhibitory control; 76% involve attention lapses). Extrinsic factors include fixture congestion and traction. Most injuries occur via non-contact mechanisms within 30–50 ms. Patterns vary by sex (53% in women during pressing/tackling; 79% in MLS without direct contact). Neuromuscular training (FIFA 11+) significantly lowers incidence. Objective clearance (LSI >90%), On-Field Rehabilitation (OFR), and delaying return to 9–12 months maintain return-to-sport rates above 80–85%. Conclusion: Preventing ACL trauma requires bridging sports medicine and management via mandatory NMT (FIFA 11+), workload monitoring, and objective return-to-play criteria.

  • Open Access

    NEXT-GENERATION DIAGNOSTICS IN ACUTE LYMPHOBLASTIC LEUKEMIA: FROM ULTRA-SENSITIVE MEASURABLE RESIDUAL DISEASE TO ARTIFICIAL INTELLIGENCE (2020–2026)

    by Natalia Skórka, Karolina Skórka, Oliwia Żmuda, Jagoda Niczyporuk, Patrycja Walo, Patrycja Okoń, Klaudia Wydra, Anna Halot, Jakub Jakubiec, Monika Zajączkowska

    Objectives: Acute lymphoblastic leukemia (ALL) diagnostics have changed rapidly in recent years, moving beyond conventional morphology, flow cytometry, and targeted molecular testing toward ultra-sensitive measurable residual disease (MRD) assays, genome-wide profiling, and artificial intelligence (AI). This review examines the major diagnostic advances introduced between 2020 and 2026 and assesses how close they are to routine clinical implementation. Methods: A structured narrative review of PubMed, Embase, Scopus, and Web of Science was performed, focusing primarily on studies published between January 2020 and August 2026, with earlier landmark studies included where necessary. Results: NGS-based MRD testing identifies residual leukemia beyond the sensitivity of conventional flow cytometry, including up to 46% of otherwise MRD-negative cases. Genome-wide approaches, particularly optical genome mapping and RNA sequencing, increase the detection of clinically relevant genomic abnormalities to approximately 90–95%. AI-based tools can substantially shorten flow-cytometric MRD analysis and support leukemia classification using routine laboratory data. However, their clinical readiness remains uneven, particularly for AI and liquid-biopsy approaches. Conclusions: Diagnostic technologies in ALL are advancing faster than the evidence guiding their clinical use. The next challenge is therefore not simply detecting more diseases but determining which findings should change treatment. Standardization, prospective validation, accessibility, and integration into clinical pathways will be essential for translating technological progress into meaningful patient benefits.

  • Open Access

    FROM MEMORIES TO DIGITAL IMMORTALITY: PSYCHOLOGICAL AND SOCIAL IMPLICATIONS OF DIGITAL AFTERLIFE IN CONTEMPORARY SOCIETY – A NARRATIVE REVIEW

    by Patrycja Okoń, Jagoda Niczyporuk, Bartosz Wójtowicz, Szymon Skrzypek, Julianna Cholewa

    Background: The accumulation of digital traces and generative AI has transformed death from a private biological event into a persistent, interactive social presence. This challenges detachment models of grief and revitalizes continuing bonds theory, while creating new vulnerabilities including fear of second loss, algorithmic grief triggers and commercialization of mourning. Methods: We conducted a narrative review following SANRA guidelines. Literature was searched across Scopus, Web of Science, PsycINFO, ACM Digital Library and Google Scholar (2010-2026, focus 2022-2026) for terms related to digital legacy, digital afterlife, online mourning, continuing bonds, griefbots/deadbots, generative ghosts and post-mortem privacy. Thirty-six influential peer-reviewed articles, monographs and conference papers were retained for thematic synthesis. Findings: We identified three interlocking transformations: from passive archiving to active simulation where griefbots generate novel utterances, from private time-limited to public, networked and algorithmically curated mourning with temporal, spatial and social expansion and platform vernaculars like GriefTok, and from peripheral to central ethics. Building on Price et al. (2025), we propose a four-type typology of digital continuing bonds: passive, active one-way, interactive, and communal. Adaptive value depends on internalized versus externalized bonds, perceived control and offline support. Generative ghosts create ambiguous presence that can scaffold coping through affective scaffolding and habits of intimacy, but also disrupt lived temporality and distort collective memory. Interpretation: Results inform clinical assessment using Dual Process Model, responsible design principles (opt-in consent, transparency, user control, sunset clause) and regulation of post-mortem privacy at EU level, given the projected 1.4-4.9 billion deceased profiles by 2100.

  • Open Access

    PEDIATRIC PSEUDOTUMOR CEREBRI SYNDROME IN A PREPUBERTAL NON-OBESE BOY: SILENT VISUAL IMPAIRMENT AND A NORMAL BRAIN MRI - A CASE REPORT

    by Bartosz Wójtowicz, Szymon Skrzypek, Patrycja Okoń, Jagoda Niczyporuk, Monika Zajączkowska, Ilona Owsiana, Magdalena Chrościńska- Krawczyk

    Background: Pseudotumor cerebri syndrome (PTCS) is characterized by elevated intracranial pressure in the setting of normal cerebrospinal fluid composition and normal or typically altered neuroimaging, once secondary causes have been excluded. In adults the disease classically affects young obese women, but in children the demographic profile is more heterogeneous, with prepubertal patients frequently being non-obese and of either sex. Early recognition is essential because untreated PTCS can cause irreversible visual loss, yet the condition is easily overlooked when the clinical presentation deviates from the adult stereotype. Case presentation: A 6-year-10-month-old prepubertal boy with a history of recurrent upper respiratory tract infections presented with a three-week history of abdominal pain, headache, vomiting, and double vision. Body mass index was 13.67 kg/m² (non-obese). Fundoscopy disclosed bilateral optic disc edema, and visual acuity was mildly reduced to 0.7 in the right eye and 0.5 in the left eye, although the child did not report visual symptoms. Magnetic resonance imaging of the brain, orbits, and whole spine was unremarkable, and computed tomography findings of low-lying cerebellar tonsils were not confirmed on MRI. Diagnostic lumbar puncture yielded clear, colorless cerebrospinal fluid with normal biochemistry and negative infectious and autoimmune workup. Acetazolamide, intravenous mannitol, and therapeutic lumbar puncture were followed by complete visual recovery (1.0 in each eye) and regression of papilledema within two weeks. Respiratory syncytial virus was treated with supportive care and amoxicillin-clavulanate because of suspected bacterial superinfection. Discussion: This case illustrates three teaching points: PTCS must be considered in prepubertal non-obese children regardless of sex; visual impairment may develop silently and recover fully with prompt treatment; and a normal brain MRI does not exclude the diagnosis, which rests on the combination of clinical features, papilledema, cerebrospinal fluid findings, and exclusion of mimics. Conclusion: Clinicians should maintain a low threshold for fundoscopy and lumbar puncture in any child with suggestive symptoms, irrespective of demographic profile, because timely treatment can prevent permanent visual loss even when the child does not report visual symptoms.

  • Open Access

    CASE REPORT: PURA SYNDROME CAUSED BY A DE NOVO c.345_346del VARIANT IN A 6-YEAR-OLD BOY WITH REFRACTORY EPILEPSY AND DIAGNOSTIC DELAY

    by Bartosz Wójtowicz, Szymon Skrzypek, Patrycja Okoń, Jagoda Niczyporuk, Julianna Cholewa, Hubert Kubiszewski, Klaudia Szukała, Magdalena Chrościńska- Krawczyk

    Background: PURA syndrome is a rare neurodevelopmental disorder caused by heterozygous pathogenic variants in the PURA gene, characterized by neonatal hypotonia, epilepsy, and developmental delay. Diagnostic delay is common when acquired neonatal insults co-exist and mask the underlying genetic etiology. Methods: We describe a 6-year-old boy with a de novo PURA c.345_346del (p.Asp116LeufsTer84) variant identified by trio clinical exome sequencing after negative SCO2 sequencing and chromosomal microarray. Clinical course, EEFeG, neuroimaging, and 6-year follow-up were analyzed retrospectively. Results: The patient presented with hypotonia, feeding difficulties, and neonatal seizures complicated by bacterial meningitis, grade I intraventricular hemorrhage, and hyperbilirubinemia. Seizures evolved into refractory epilepsy with tonic, hypermotor, and focal impaired awareness seizures despite four antiseizure medications. Additional features included non-verbal status, GMFCS V, strabismus, cryptorchidism, and hypothyroidism requiring replacement therapy. Conclusion: Co-occurring acquired insults may mask monogenic etiology and prolong diagnostic odyssey. Early access to exome sequencing and multidisciplinary follow-up are critical for family counseling and care planning.

  • Open Access

    AUTOIMMUNE EPILEPSY: THE UNDERESTIMATED DIAGNOSIS - FROM RED FLAGS TO IMMUNOTHERAPY

    by Szymon Skrzypek, Oliwia Żmuda, Natalia Skórka, Karolina Skórka, Jagoda Niczyporuk, Bartosz Wójtowicz, Patrycja Okoń, Weronika Skrzypek, Magdalena Chrościńska-Krawczyk

    Autoimmune-associated epilepsy (AAE) is the epilepsy phenotype most likely to be missed in neurology clinics. Neural autoantibodies are identified in a substantial fraction of adults with epilepsy of unknown aetiology, mostly undiagnosed before testing, and in a sizeable proportion of new-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES). The barrier to recognition is not the absence of effective therapy, but the absence of systematic testing: autoimmune epilepsy is not rare; it is rarely tested. This review argues for a shift from antibody-driven testing ("test when encephalitis is suspected") to syndrome-driven testing ("epilepsy-plus" phenotypes triggering a reflex panel). We synthesise the 2016-2026 literature across three axes. First, an antibody-by-antibody guide (Table 1) contrasts surface-antigen syndromes (LGI1, NMDAR, CASPR2, GABA-B, GABA-A, AMPA) with the intracellular-antigen GAD65 syndrome. Second, a twelve-domain Red Flag Checklist (Table 2) operationalises the "epilepsy-plus" concept, with a ≥2-flag trigger rule mandating reflex testing of paired serum and cerebrospinal fluid. Third, a 2026 immunotherapy algorithm (Table 3) stratifies first-line, second-line, and refractory therapy on the principle that timing is the active ingredient. We address three ongoing debates - GAD65 low- versus high-titre pathogenicity, seronegative AAE, and immunotherapy duration - proposing a risk-stratified, treat-to-remission framework. The cost of delay is measurable in hippocampi, cognitive function, and lives; the barrier is not cost but habit.

  • Open Access

    TEN-YEAR KETOGENIC DIET AS PRIMARY THERAPY IN SCN2A-RELATED DRUG-RESISTANT DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY: LONG-TERM EFFICACY, SAFETY, AND MULTISYSTEM OUTCOMES

    by Bartosz Wójtowicz, Szymon Skrzypek, Oliwia Żmuda, Jakub Jasionka, Jagoda Niczyporuk, Patrycja Okoń, Jan Lejman, Magdalena Chrościńska- Krawczyk

    Objective: This case study reports a decade-long (2016–2026) follow-up of a girl with gene-confirmed SCN2A-related developmental and epileptic encephalopathy (DEE) in whom the ketogenic diet (KD) was used as primary therapy after failure of eight sequential antiseizure regimens. Methods: Retrospective analysis of hospital records (2013–2026) covering perinatal history, genetic diagnosis, drug therapy, dietary protocol modifications, and serial laboratory, imaging, and electrophysiological surveillance. Results: Classic KD initiated at age 2 years 9 months produced rapid seizure reduction (>50%), enabling complete withdrawal of all conventional ASMs by February 2017. The diet was maintained continuously for over 10 years, including through emergency craniotomy for traumatic intracranial hemorrhage in April 2018. Adjunctive CBD/THC oil was used from 2017, with a transient valproate retrial in December 2022. Multisystem complications (hypercalciuria, lumbar osteopenia with BMD Z-score −2.7, transient dyslipidemia) were managed with potassium citrate, vitamin D3/calcium supplementation, and dietary ratio adjustments; no nephrolithiasis or KD-attributable cardiac complications occurred. Growth remained within normal range without gastrostomy. Conclusions: Long-term KD as primary non-pharmacological therapy is feasible and safe in SCN2A-related DEE, permitting complete ASM cessation, provided multidisciplinary metabolic and bone surveillance is maintained.

  • Open Access

    Environmental determinants of multiple sclerosis – a focused review

    by Jagoda Niczyporuk, Patrycja Okoń, Bartosz Wójtowicz, Julianna Cholewa, Anna Jamroz-Wiśniewska, Konrad Rejdak

  • Open Access

    Where does this panic attack come from? - about anxiety, its types and forms of therapy - Narrative review

    by Patrycja Okoń, Aleksandra Nowak, Gabriela Nowak, Zofia Nurek

    Introduction: Anxiety disorders are common mental health problems that impact social functioning and public health. They result from interactions between environmental, biological, and genetic factors. Research focuses on brain mechanisms and structural changes linked to anxiety. Advances in neuroimaging and genetics allow for better identification of biomarkers, aiding diagnosis and therapy. This paper discusses the neurobiology of anxiety disorders and their clinical relevance, especially anxiety attacks. Material and methods: This study is a narrative review of literature from the last five years in Scopus and PubMed on anxiety disorders with panic attacks. English-language publications, including original papers, systematic reviews, meta-analyses, and reviews, were considered. The aim was to provide a concise discussion of key neurobiological mechanisms, clinical concepts, and current therapeutic approaches. Results: Research indicates that amygdala hyperactivity and reduced hippocampal volume correlate with intensified anxiety symptoms. Genetic variants predisposing to anxiety disorders have been identified. Dysfunction in serotonergic and GABAergic transmission plays a key role in emotion regulation. Stressful events in childhood and adolescence can permanently alter brain development, increasing the risk of later disorders. Findings also show that different anxiety disorders have distinct neurobiological profiles and functional consequences. Conclusions: Anxiety disorders thus have a clear neurobiological basis, which can be identified through modern research methods. Genetic and environmental factors jointly increase the brain’s sensitivity to anxiety. Early psychological intervention is crucial, as it may prevent lasting changes in the nervous system Neurobiological differences between disorders highlight the need for individualized treatment. Current evidence supports the combined use of pharmacotherapy and psychotherapy targeting specific pathophysiological mechanisms.